Pharmacokinetic Profile of High Doses of Aprotinin in Patients Undergoing Primary Elective Hysterectomy

摘要: 24 female patients aged less than 60 years (mean 42.3 years), and 23 more 70.1 years) who were undergoing primary elective abdominal or vaginal hysterectomy took part in 2 randomised, unblinded, parallel group studies to investigate the pharmacokinetic profile of high doses aprotinin during clinical administration. In each study, first treatment received a single intravenous infusion 1 million kallikrein inactivator units (KJU) [140mg] after start operation (first incision) over 30 minutes, while second KIU (280mg) same manner. Blood urine samples for assays collected 36.5-hour period following infusion. The results study with have been reported earlier, are presented here time. addition, meta-analysis was performed. both suggest that aprotinin, infused intravenously displays dose-proportional characteristics dose range studied. plasma concentrations decrease biphasically. total urinary excretion unchanged drug is very low, but appears increase dose. Intravenous well tolerated, employed similar respect associated intraoperative blood loss. pharmacokinetics years.